ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation: Joint opinion of task force on European regulatory affairs and working group accreditation and ISO/CEN standards of the European Federation of Clinical Chemistry and Laboratory Medicine
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
The EU In-Vitro Diagnostic Device Regulation (IVDR) aims for transparent risk-and purpose-based validation of diagnostic devices, traceability of results to uniquely identified devices, and post-market surveillance. The IVDR regulates design, manufacture and putting into use of devices, but not medical services using these devices. In the absence of suitable commercial devices, the laboratory can resort to laboratory-developed tests (LDT) for in-house use. Documentary obligations (IVDR Art 5.5), the performance and safety specifications of ANNEX I, and development and manufacture under an ISO 15189-equivalent quality system apply. LDTs serve specific clinical needs, often for low volume niche applications, or correspond to the translational phase of new tests and treatments, often extremely relevant for patient care. As some commercial tests may disappear with the IVDR roll-out, many will require urgent LDT replacement. The workload will also depend on which modifications to commercial tests turns them into an LDT, and on how national legislators and competent authorities (CA) will handle new competences and responsibilities. We discuss appropriate interpretation of ISO 15189 to cover IVDR requirements. Selected cases illustrate LDT implementation covering medical needs with commensurate management of risk emanating from intended use and/or design of devices. Unintended collateral damage of the IVDR comprises loss of non-profitable niche applications, increases of costs and wasted resources, and migration of innovative research to more cost-efficient environments. Taking into account local specifics, the legislative framework should reduce the burden on and associated opportunity costs for the health care system, by making diligent use of existing frameworks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The regulatory classification depends on the software's intended purpose; if primarily associated with In Vitro Diagnostic (IVD) data, it falls under IVDR [132, 134], otherwise, it falls under MDR [133].”
From Machine learning-based clinical decision support using laboratory data (2024) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Organization for Standardization
(2011) · SpringerReference · doi:10.1007/springerreference_16847 · Cited by 12,534
Thompson, M., Ellison, S. L. R., & Wood, R. (2002) · Pure and Applied Chemistry · doi:10.1351/pac200274050835 · Cited by 2,478
Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.019 · Cited by 585
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5997 · Cited by 494
Multidisciplinary cancer conferences: A systematic review and development of practice standards
Wright, F. C., De Vito, C., Langer, B., & Hunter, A. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.025 · Cited by 307
Standard IEC 62304 - Medical device software - Software lifecycle processes
Jordan, P. (2006) · IET Seminar on Software for Medical Devices · doi:10.1049/ic:20060141 · Cited by 244
From biomarkers to medical tests: the changing landscape of test evaluation
Horvath, A. R., Lord, S. J., StJohn, A., Sandberg, S., Cobbaert, C. M., Lorenz, S., Monaghan, P. J., Verhagen-Kamerbeek, W. D. J., Ebert, C., & Bossuyt, P. M. M. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.09.018 · Cited by 203
Self-citationHealth care process modelling: which method when?
Jun, G. T., Ward, J., Morris, Z., & Clarkson, J. (2009) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzp016 · Cited by 162
Naito, Y., Aburatani, H., Amano, T., Baba, E., Furukawa, T., Hayashida, T., Hiyama, E., Ikeda, S., Kanai, M., Kato, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01831-6 · Cited by 117
Panteghini, M., Ceriotti, F., Jones, G. R. D., Oosterhuis, W. P., Plebani, M., & Sandberg, S. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0772 · Cited by 84
Self-citationDelic, S., Rose, D., Kern, W., Nadarajah, N., Haferlach, C., Haferlach, T., & Meggendorfer, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14269 · Cited by 80
The Poly Implant Prothèse breast prostheses scandal: Embodied risk and social suffering
Greco, C. (2015) · Social Science & Medicine · doi:10.1016/j.socscimed.2015.10.068 · Cited by 69
Five main processes in healthcare: a citizen perspective: Figure 1
Bergman, B., Neuhauser, D. B., & Provost, L. (2011) · BMJ Quality & Safety · doi:10.1136/bmjqs.2010.046409 · Cited by 67
Internal quality control: best practice
Kinns, H., Pitkin, S., Housley, D., & Freedman, D. B. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201661 · Cited by 66
Biomarker development targeting unmet clinical needs
Monaghan, P. J., Lord, S. J., John, A. S., Sandberg, S., Cobbaert, C. M., Lennartz, L., Verhagen-Kamerbeek, W. D. J., Ebert, C., Bossuyt, P. M., & Horvath, A. R. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.06.037 · Cited by 66
Self-citationOrth, M., Averina, M., Chatzipanagiotou, S., Faure, G., Haushofer, A., Kusec, V., Machado, A., Misbah, S. A., Oosterhuis, W., Pulkki, K., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204734 · Cited by 59
Self-citationEvidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing
Christenson, R. H. (2007) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/000456307780118127 · Cited by 55
Bank, P. C. D., Jacobs, L. H. J., van den Berg, S. A. A., van Deutekom, H. W. M., Hamann, D., Molenkamp, R., Ruivenkamp, C. A. L., Swen, J. J., Tops, B. B. J., Wamelink, M. M. C., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1384 · Cited by 48
Self-citationSpitzenberger, F., Patel, J., Gebuhr, I., Kruttwig, K., Safi, A., & Meisel, C. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00323-7 · Cited by 48
Accreditation process in European countries – an EFLM survey
Boursier, G., Vukasovic, I., Brguljan, P. M., Lohmander, M., Ghita, I., Bernabeu Andreu, F. A., Barrett, E., Brugnoni, D., Kroupis, C., Sprongl, L., et al. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0780 · Cited by 42
Self-citationCancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Aleksakhina, S. N., & Imyanitov, E. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010931 · Cited by 41
Vermeersch, P., Aelst, T. V., & Dequeker, E. M. C. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0804 · Cited by 37
An approach for determining allowable between reagent lot variation
Lantman, M. V. S., Çubukçu, H. C., Boursier, G., Panteghini, M., Bernabéu-Andréu, F. A., Milinković, N., Brguljan, P. M., Linko, S., Brugnoni, D., O’Kelly, R., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0083 · Cited by 34
Self-citationBeer, R. J. A. C. R.-D., Wielders, J. P. M., Boursier, G., Vodnik, T., Vanstapel, F. J. L. A., Huisman, W., Vukasović, I., Vaubourdolle, M., Sönmez, Ç., Linko, S., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1053 · Cited by 33
Self-citationTowards precision medicine in lymphoid malignancies
Bühler, M. M., Martín-Subero, J. I., Pan‐Hammarström, Q., Campo, E., & Rosenquist, R. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13423 · Cited by 32
Cobbaert, C. M., Capoluongo, E., Vanstapel, F. J. L. A., Bossuyt, P. M., Bhattoa, H. P., Nissen, P. H., Orth, M., Streichert, T., Young, I. S., Macintyre, E. A., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0975 · Cited by 26
Self-citationvan Duijl, T. T., Ruhaak, L. R., Smit, N. P. M., Pieterse, M., Romijn, F. P. H. T. M., Dolezal, N., Drijfhout, J. W., de Fijter, J. W., & Cobbaert, C. M. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00532 · Cited by 25
Self-citationThelen, M., Vanstapel, F. J. L. A., Κroupis, C., Vukasović, I., Boursier, G., Barrett, E. J., Bernabéu-Andréu, F. A., Brguljan, P. M., Brugnoni, D., Lohmander, M., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0257 · Cited by 24
Self-citationLaboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks
Vogeser, M., Brüggemann, M., Lennerz, J., Stenzinger, A., & Gassner, U. M. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab215 · Cited by 22
Complex analytical procedures in diagnostic laboratories and the IVDR
Vogeser, M., & Brüggemann, M. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1775 · Cited by 19
Easwar, A., & Siddon, A. J. (2021) · Life · doi:10.3390/life11111158 · Cited by 19
Improving the laboratory result release process in the light of ISO 15189:2012 standard
Çubukçu, H. C., Vanstapel, F. J. L. A., Thelen, M., Andreu, F. A. B., Lantman, M. V. S., Brugnoni, D., Brguljan, P. M., Milinković, N., Linko, S., Vaubourdolle, M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.08.013 · Cited by 17
Self-citationvan Deutekom, H. W. M., & Haitjema, S. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0278 · Cited by 17
Hermans, A., Maliepaard, M., Boon, W., & Pasmooij, A. M. G. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2087508 · Cited by 15
The gaps between the new EU legislation on in vitro diagnostics and the on-the-ground reality
Horgan, D., Plebani, M., Orth, M., Macintyre, E. A., Jackson, S., Lal, J. A., Dube, F., Kozaric, M., Tumiene, B., Salgado, R., et al. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1051 · Cited by 10
Self-citationIn vitro diagnostic medical device regulation (IVDR): the end of laboratory developed tests (LDT)?
Barberis, M. C. P. (2021) · Pathologica · doi:10.32074/1591-951x-237 · Cited by 9
Akkreditierung in der Pathologie
Röcken, C., & Manke, H. (2009) · Der Pathologe · doi:10.1007/s00292-009-1237-x · Cited by 8
Maliepaard, M., Nibi, P., Nibi, G., & Pasmooij, A. M. G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.893028 · Cited by 8
Hoffmüller, P., Brüggemann, M., Eggermann, T., Ghoreschi, K., Haase, D. T., Hofmann, J., Hunfeld, K., Koch, K., Meisel, C., Michl, P., et al. (2021) · PubMed Central · doi:10.18154/rwth-conv-246988 · Cited by 7
Self-citationVogeser, M., Brüggemann, M., Lennerz, J. K., Stenzinger, A., & Gassner, U. M. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac048 · Cited by 7
Research works printed but not linked: 15
- 3. European Parliament and Council Regulation (EU) 2017/745 of 5 April 2017 on medical devices: O ffi cial Journal of the European Union; 2017, vol 117:1 -175 pp. Available from: http://data.europa.eu/eli/reg/2017/ 745/oj [Accessed 3 Jun 2022].
- 4. European Parliament and Council Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices: O ffi cial Journal of the European Union; 2017, vol 117:176 -332 pp. Available from: http://data. europa.eu/eli/reg/2017/746/oj [Accessed 5 Jul 2022].
- 8. European Parliament and Council Regulation (EU) 2022/112 of 25 January 2022 amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices: O ffi cial Journal of the European Union; 2022, vol 19:3 -6 pp. Available from: http://data.europa.eu/eli/reg/2022/112/oj [Accessed 4 Dec 2022].
- European Commission Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 (Text with EEA relevance): Official Journal of the European Union
- 38. European Commission Commission Implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common speci fi cations for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746 (Text with EEA relevance): O ffi cial Journal of the European Union; 2022, vol 178:3 -56 pp. Available from: http://data. europa.eu/eli/reg\_impl/2022/1107/oj [Accessed 21 Nov 2022].
- 44. Patra KP, De Jesus O. Sentinel event: StatPearls Publishing; 2021. PMID: 33232058. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK564388/[Accessed 11 Jun 2022].
- 49. Janssens PMW. Lessen uit en over de analyse van bijzondere vochten. Ned Tijdschr Klin Chem Lab 2017;42:2 -15.
- European Parliament and Council Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance: Official Journal of the European Union
- 60. European Parliament and Council Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance: O ffi cial Journal of the European Union; 2014, vol 158:1 -76 pp. Available from: http:// data.europa.eu/eli/reg/2014/536/oj [Accessed 4 Dec 2022].
- European Parliament and Council. Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation): Official Journal of the European Union
- 67. European Parliament and Council. Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation): O ffi cial Journal of the European Union; 2016, 119:1 -88 pp. Available from: http://data.europa.eu/eli/reg/2016/679/oj [Accessed 4 Dec 2022].
- European Parliament and Council Directive 2014/24/EU of 26 February 2014 on public procurement and repealing Directive 2004/18/EC: Official Journal of the European Union
- 72. European Parliament and Council Directive 2014/24/EU of 26 February 2014 on public procurement and repealing Directive 2004/18/EC: O ffi cial Journal of the European Union; 2014, vol 94: 1 -206 pp. Available from: http://data.europa.eu/eli/dir/2014/24/ 2022-01-01 [Accessed 4 Dec 2022].
- European Council, Council regulation (EC) No 1/2003 of 16 December 2002 on the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty: Official Journal of the European Union
- 73. European Council, Council regulation (EC) No 1/2003 of 16 December 2002 on the implementation of the rules on competition laid down in Articles 81 and 82 of the Treaty: O ffi cial Journal of the European Union; 2003, vol 1:1 -25 pp. Available from: http://data.europa.eu/eli/reg/ 2003/1/oj [Accessed 4 Dec 2022].
Cited by
Machine learning-based clinical decision support using laboratory data
Çubukçu, H. C., Topcu, D. İ., & Yenice, S. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1037 · Cited by 66
“The regulatory classi fi cation depends on the software ’ s intended purpose; if primarily associated with In Vitro Diagnostic (IVD) data, it falls under IVDR [132, 134], otherwise, it falls under MDR [133].”
BackgroundSelf-citationCurrent HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
Guffanti, F., Mengoli, I., & Damia, G. L. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1405361 · Cited by 47
Linko, S., Boursier, G., Bernabéu-Andréu, F. A., Dzneladze, N., Vanstapel, F. J. L. A., Brguljan, P. M., Trajkovska, K. T., Mehay, H., Panteghini, M., Brugnoni, D., et al. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-1451 · Cited by 19
Self-citationZaninotto, M., Agnello, L., Dukić, L., & Akhvlediani, L. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2024-0308 · Cited by 17
Review—Aptamers and Biomimetic Receptors in Biosensing: Innovations and Applications
Tripathi, A., Pandey, V. K., Mishra, H., Rustagi, S., Dar, A. H., & Malik, S. (2024) · Journal of The Electrochemical Society · doi:10.1149/1945-7111/ad3202 · Cited by 14
Metadata
- Authors
- Vanstapel, F. J. L. A., Orth, M., Streichert, T., Capoluongo, E. D., Oosterhuis, W. P., Çubukçu, H. C., Bernabeu-Andreu, F. A., Thelen, M., Jacobs, L. H. J., Linko, S., Bhattoa, H. P., Bossuyt, P. M. M., Meško Brguljan, P., Boursier, G., Cobbaert, C. M., & Neumaier, M.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Heidelberg University (DE)
- University of Cologne (DE)
- University of Naples Federico II (IT)
- Department of Clinical Chemistry , Reinier Haga Medical Diagnostic Centre , Delft , The Netherlands
- Ministry of Health (TR)
- Servicio Bioquímica Análisis Clínicos , Hospital Universitario Puerta de Hierro Majadahonda (Madrid) , Majadahonda , Spain
- Radboud University Medical Center (NL)
- Meander Medisch Centrum (NL)
- Linko Q-Solutions , Helsinki , Finland
- University of Debrecen (HU)
- Amsterdam University Medical Centers (NL)
- Department of Clinical Chemistry , University Clinic for Respiratory and Allergic Diseases Golnik , Golnik , Slovenia
- Université de Montpellier (FR)
- Leiden University Medical Center (NL)
- Corresponding author
- Vanstapel, Florent J.L.A.
- ORCID
- Vanstapel, Florent J.L.A.
- Orth, Matthias
- Streichert, Thomas
- Capoluongo, Ettore D.
- Oosterhuis, Wytze P.
- Çubukçu, Hikmet Can
- Bernabeu-Andreu, Francisco A.
- Thelen, Marc
- Jacobs, Leo H.J.
- Linko, Solveig
- Bhattoa, Harjit Pal
- Bossuyt, Patrick M.M.
- Meško Brguljan, Pika
- Boursier, Guilaine
- Cobbaert, Christa M.
- Neumaier, Michael
- Venue
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Publisher
- Walter de Gruyter GmbH
- Published
- 2023-01-31
- Volume
- 61
- Issue
- 4
- Pages
- 608-626
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W4318542353
- Semantic Scholar
- 3a71d0ec1c7cd61edd29254efa52f5560331d9b7
- Cited by
- 45
- References
- 42
- Citations by year
- 2026: 9 · 2025: 15 · 2024: 12 · 2023: 9
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- public-domain
- Locations
- Clinical Chemistry and Laboratory Medicine (CCLM) (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, public-domain)
- Lirias (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- ISO 15189, laboratory-developed tests, IVDR, in vitro diagnostic regulation, quality management systems, post-marketing surveillance, regulatory burden
- MeSH terms
- European Union, Humans, Reagent Kits, Diagnostic, Clinical Laboratory Services
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.